SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q1 Trading Update

18 Apr 2019 07:00

RNS Number : 5559W
Rentokil Initial PLC
18 April 2019
 

 

RENTOKIL INITIAL PLC (RTO)

FIRST QUARTER TRADING UPDATE

18 April 2019

 

(£m)

 

Q1 2019

Growth

 

 

AER

AER

CER

Ongoing Revenue1

 

603.6

10.6%

8.9%

Revenue

 

607.4

10.3%

8.6%

 

Overview

Trading has started well across our businesses in Q1 with Ongoing Revenue1 increasing by 8.9%, of which 4.0% was Organic Revenue2 growth (Q1 2018: 3.2%, FY 2018: 3.7%) and 4.9% was from acquisitions.

Ongoing Revenue in Pest Control grew by 12.0%, 5.0% Organic (Q1 2018: 4.7%), with good performances being delivered across both Growth and Emerging markets, which rose by 12.1% and 11.5% respectively. Hygiene has made a very positive start to the year, with Ongoing Revenue growth of 7.2% and Organic Revenue growth of 4.3% (Q1 2018: 1.8%). Ongoing Revenue in our Protect & Enhance markets was in line with Q1 2018.

M&A

​We signed eight acquisitions in Q1, four in Pest Control (primarily in North America and Latin America) and four in Hygiene, with combined annualised revenues of c. £29m in the year prior to purchase. We are encouraged about our prospects for further M&A this year and our pipeline of value-enhancing opportunities is strong. Our guidance for M&A spend in 2019 remains in the range of £200m to £250m.  

Pension Scheme and Funding

In December 2018 the Company reached agreement for a bulk annuity insurance 'buy-in' for its UK Defined Benefit Pension scheme ("the Scheme") in contemplation of a full 'buy-out' which is expected to complete in early 2020. Good progress towards buy-out is being made and we now anticipate a pre-tax cash surplus of c. £40m will be returned to the Company on completion.

Ahead of the refinancing of our €500m bond maturing in September this year, we are intending to hold a non-deal, bond investor education roadshow in London, France, Germany, the Netherlands, Nordics and Asia. We will release further details in due course.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have had a good start to 2019 and I'm pleased with our performance in the first three months of this year. I am confident of another year of successful growth for the Company, in line with market expectations."

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

 

 

 

 

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

 

 

 

 

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2018 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTZMGMDRNMGLZM
Date   Source Headline
28th Jul 20253:00 pmRNSHolding(s) in Company
10th Jul 202511:00 amRNSHolding(s) in Company
1st Jul 202510:25 amRNSTotal Voting Rights
10th Jun 202510:05 amRNSAdditional Listing
3rd Jun 20254:00 pmRNSDirector/PDMR Shareholding
28th May 20257:00 amRNSSale of France Workwear
19th May 20252:30 pmRNSDirector/PDMR Shareholding
7th May 20254:15 pmRNSResult of AGM
7th May 20257:01 amRNSDirectorate Change: Appointment of NEDs
7th May 20257:00 amRNSDirectorate Change: Chief Executive to retire
28th Apr 20252:30 pmRNSIssue of Debt
17th Apr 20252:20 pmRNSHolding(s) in Company
17th Apr 20257:00 amRNSQ1 Trading Update
9th Apr 202510:25 amRNSHolding(s) in Company
1st Apr 20252:15 pmRNSNotice of Q1 Trading Update and Management Call
1st Apr 202510:25 amRNSBlock listing Interim Review
27th Mar 202510:25 amRNSDirector/PDMR Shareholding
26th Mar 202510:30 amRNSAnnual Financial Report
14th Mar 202510:00 amRNSDirector/PDMR Shareholding
6th Mar 20257:00 amRNSFinal Results
28th Jan 20257:00 amRNSTrading Update (unaudited)
14th Jan 202511:15 amRNSHolding(s) in Company
13th Jan 202511:15 amRNSHolding(s) in Company
13th Dec 20249:30 amRNSDirector/PDMR Shareholding
25th Nov 20247:00 amRNSDirectorate Change
12th Nov 202410:30 amRNSHolding(s) in Company
8th Nov 202410:30 amRNSHolding(s) in Company
17th Oct 20247:00 amRNSQ3 Trading Update
1st Oct 20242:00 pmRNSBlock listing Interim Review
25th Sep 20247:00 amRNSAppointment of Non-Executive Director
19th Sep 202410:30 amRNSDirector/PDMR Shareholding
11th Sep 20247:00 amRNSTrading Update
10th Sep 202410:30 amRNSHolding(s) in Company
5th Sep 202411:08 amRNSHolding(s) in Company
25th Jul 20247:00 amRNS2024 Interim Results
10th Jul 20244:35 pmRNSHolding(s) in Company
26th Jun 20245:12 pmRNSDirector/PDMR Shareholding
26th Jun 202411:08 amRNSHolding(s) in Company
17th May 20243:30 pmRNSDirector/PDMR Shareholding
8th May 20242:00 pmRNSResult of AGM
29th Apr 20243:00 pmRNSHolding(s) in Company
23rd Apr 20249:30 amRNSHolding(s) in Company
18th Apr 20247:00 amRNSQ1 Trading Update
2nd Apr 20241:28 pmRNSBlock listing Interim Review
2nd Apr 202412:17 pmRNSTotal Voting Rights
27th Mar 202410:23 amRNSAnnual Financial Report
19th Mar 20242:05 pmRNSAdditional Listing
14th Mar 202410:19 amRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSFinal Results
1st Dec 20237:00 amRNSNorth American Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.